Clinical Trial

High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The investigators were to explore whether high-dose Furmonertinib, compared with osimertinib, could achieve longer survival in patients with EGFR-mutated NSCLC with CNS metastasis.
Trial Details
NCT Number NCT06319950
Lead Sponsor Taizhou Hospital
Conditions Lung Cancer, Nonsmall Cell
Enrollment 255 participants
Start Date 2024-04-01
Primary Completion 2026-12-30 (estimated)
Study Completion 2026-12-30 (estimated)
Updated on ClinicalTrials.gov 2024-03-20